Brief: Compugen Announces Lung Cancer Treatment To Enter Phase 1/2 Study
19/08/2021 12:47
Aug 19 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN ANNOUNCES BISPECIFIC ANTIBODY DERIVED FROM COM902
TO
ENTER CLINICAL DEVELOPMENT
* COMPUGEN LTD - PHASE 1/2 CLINICAL STUDY WILL EVALUATE
AZD2936, A
TIGIT/PD-1 BISPECIFIC ANTIBODY OF ASTRAZENECA, IN NON-SMALL CELL
LUNG CANCER
Source text for Eikon: ID:nPn5TrTdZa
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025